Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Human Immune System Likened to Model of Military Efficiency

Thomas R. Collins  |  Issue: April 2017  |  April 20, 2017

It’s a system under “very tight regulation,” Dr. Torgerson said, with factors essentially holding the system at bay at various levels, such as factor H at the C3 level, and CD59 at the level of C8 and 9.

Defects in the complement system can lead to profound problems. People with a C1 deficiency have a 90% chance of developing lupus, Dr. Torgersen said. Those deficient in C2—the most common complement deficiency—have a 40% chance of developing lupus and require regular lupus screening.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients can be treated by replenishing complement via fresh frozen plasma, he said. Patients deficient in C1 inhibition could benefit from a recombinant C1 inhibitor. Eculizumab binds to C5, blocking the formation of the membrane attack complex. Its price is exorbitant, but it works well in patients who really need it, he said.

Phagocyte Compartment

Phagocytes, part of innate immunity, roll down the walls of blood vessels, sticking and releasing, sampling their environment as they go. When they encounter an infection, cytokines and chemokines are sent out by the tissue cells, essentially asking for help.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Torgersen calls phagocytes the Marines of immunity because neutrophils are then produced and crawl out into the tissue to the site of the infection and gorge themselves on bacteria or other invaders. After that, they throw up on themselves, as he put it, presenting what they’ve eaten on major histocompatibility complex cells in a display that’s arrayed like a hot dog in a bun to appeal to T cells and other immune cells.

People with deficiency in this compartment—causing adhesion deficiency, preventing phagocytes from sticking and rolling, or sticking down hard when there’s an infection to fight, or causing problems with phagocytes’ digestive ability—tend to get recurrent skin and soft tissue abscesses and chronic granulomatous disease.

Colchicine interferes with the formation of microtubules that neutrophils need to survive. And steroid treatment, although not specific to phagocyte function, acts as a brake so that neutrophils don’t migrate and function as well.

B Cell Compartment

B cells are like the Air Force of the immune system, deploying antibodies like cruise missiles, Dr. Torgersen said. They have a complex maturing process, going from immature cells in the bone marrow, then migrating to the periphery as they mature, then becoming fully mature as memory cells or plasma cells, factories, in effect, that produce antibodies, he said.

Patients on repeated treatments with B cell-depleting therapies, who are deficient in B cells or antibodies, can have recurrent infections, such as sinus infections or pneumonia.

Page: 1 2 3 | Single Page
Share: 

Filed under:Meeting ReportsResearch Rheum Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)B cellsImmunologyResearchrheumatologyT cell

Related Articles

    Exploring the Complement System in Human Disease

    February 1, 2010

    Novel disease associations revealed by whole genome screens

    Kateryna Kon / Shutterstock.com

    How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease

    December 17, 2017

    Anemia is common in patients with systemic rheumatic disease, yet it may not get the attention it deserves. Anemia can result from chronic inflammation, treatment side effects or other disease factors, or it may signal an unrelated condition. Although diagnosis and treatment of anemia are sometimes challenging, clinicians must do their utmost to rigorously investigate…

    Diagnosis: Myopathy

    July 1, 2009

    Presentation and evaluation of metabolic causes

    Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease

    January 1, 2010

    A perspective on B cell–targeted therapies in autoimmune disease

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences